1. South Korea Stocks

  2. •

    Health services

  3. •

    Medical/Nursing services
Genomictree, Inc.

Genomictree, Inc.

KKRX:228760
9,400.00
KRW
+130.00
(+1.40%)
-381.71EPS
271.75BMarket Cap
Nov 06Next Earn
Genomictree, Inc.
KRX:228760
(Korea Stock Exchange)

Recent

price

9,400.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
KRW
95.6
14.68
31.77
24.61
14.72
61.97
248.78
1,423.29
152.63
98.94
156.5
122.32
Revenue per Share
-112
-55.17
-148.02
-158
-533
-590
-553
-316
-391
-429
-374
-374.75
Basic EPS, GAAP
-92.35
-23.91
-177.88
-308.92
-589.61
-651.5
-941.88
117.31
-498.75
-677.93
-538.51
-520.37
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-28.1
252.77
534.61
695.03
5,449.73
4,766.06
5,643.25
5,177.78
5,278.29
5,163.99
4,691.64
4,959.68
Book Value per Share
-57.45
212.61
480.99
634.92
5,397.6
4,717.93
5,561.13
5,102.52
5,220.87
5,111.89
4,641.05
4,906.55
Tangible Book Value per Share
11
37
14
16
19
20
21
21
22
24
24
24
Basic Weighted Avg Shares
1,049
548
454
387
282
1,239
5,140
29,866
3,418
2,362
3,760
2,946
Sales/Revenue/Turnover
-69.29
-236.13
-442.36
-665.15
-3,660.22
-1,001.61
-191.75
8.05
-506.24
-648.24
-300.47
-398.4
Operating Margin (%)
98
117
135
188
490
908
1,022
1,335
1,178
1,186
1,065
1,185
Depreciation Expense
-1,228
-2,061
-2,113
-2,484
-10,195
-11,795
-11,425
-6,631
-8,756
-10,242
-8,986
-9,027
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-117.15
-375.84
-465.87
-642.07
-3,619.97
-952.1
-222.28
-22.2
-256.17
-433.57
-238.98
-306.36
Profit Margin (%)
2,565
1,371
5,823
6,511
100,594
101,211
132,185
64,557
90,090
92,912
74,460
79,831
Working Capital
- -
- -
- -
400
1,200
11,261
38,179
85
98
60
25
11
LT Debt
-389
3,498
8,296
11,085
108,821
95,255
115,101
107,557
125,032
124,320
115,310
121,931
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
-35.83
-25.64
-16.99
-11.55
-10.88
-5.98
-7.56
-8.24
-7.52
-7.56
Return on Common Equity (%)

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
2,343
37
33
LT Borrowings
- -
- -
- -
LT Finance Leases
25
18
11
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
25
25
25
Market Capitalization
673,253
421,856
271,754

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
78,905
77,145
81,165
Cash, Cash Equivalents & STI
77,366
75,385
79,181
Accounts Receivable, Net
384
234
366
Inventories
265
328
347
Total Current Liabilities
4,445
1,356
1,334
Payables & Accruals
- -
- -
- -
ST Debt
2,343
37
33
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
6.3%
4.54%
-7.25%
Free Cash Flow
-18.07%
-118.43%
-20.06%
Net Income, GAAP
40.56%
-1.67%
-12.27%
Sales/Revenue/Turnover
96.87%
147.14%
59.17%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
285
560
693
824
2,362
2025
316
1,721
897
826
3,760
2026
382
842
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-118
-118
-129
-71.64
-429
2025
-121
-59
-113.4
-80.75
-374
2026
-80.2
-100.58
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Hims & Hers Health, Inc. (NYSE:HIMS)
Mobile-health Network Solutions (NASDAQ:MNDR)
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)
Dr. Lal PathLabs Limited (NSE:LALPATHLAB)
Tenon Medical, Inc. (NASDAQ:TNON)
Teladoc Health, Inc. (NYSE:TDOC)
Business
Genomictree Inc. (228760.KS) develops and commercializes epigenomic biomarker-based molecular diagnostics for early cancer detection and infectious diseases; its core products include EarlyTect C, a non-invasive stool-based colorectal cancer screening test measuring methylated syndecan-2 DNA with 90% sensitivity and specificity, EarlyTect L for lung cancer risk assessment in pulmonary nodule patients via serum epigenetic markers, EarlyTect B for bladder cancer detection in hematuria patients using genetic and epigenetic markers, and AccuraDTect SARS-CoV-2 RT-qPCR kits with related nucleic acid transport media. The company, founded in 2000 and headquartered in Daejeon, South Korea, operates primarily in the biotechnology sector targeting healthcare providers, high-risk patients, and general screening populations across Asia and the United States. In recent developments, Genomictree established U.S. subsidiary Promis Diagnostics Inc. in 2019, which secured approximately $40.8 million in funding by 2020 for FDA clinical studies and premarket approval of colorectal and bladder cancer diagnostics, appointed Dr. Theo deVos as Senior Vice President in June 2025 to bolster U.S. operations, and received breakthrough device designation from the FDA for its EarlyTect BCD bladder cancer test in 2023 while launching laboratory-developed test services in the U.S.